THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha® (evolocumab) to ...

--Amgen today announced new Repatha ® combined data from the Phase 3 FOURIER and FOURIER Open Label Extension studies and the Phase 2 OCEAN- DOSE study of investigational olpasiran, an siRNA that ...

Repatha (evolocumab) isn’t known to interact with other medications, supplements, herbs, vitamins, vaccines, or lab tests. There are no known direct interactions between Repatha and alcohol. However, ...

Most Medicare drug plans cover Repatha (evolocumab). This includes stand-alone Part D prescription drug plans and Medicare Advantage plans that include prescription drug coverage. Doctors prescribe ...

Previously, Repatha was indicated to reduce the risk of MACE in patients with established cardiovascular disease. The Food and Drug Administration (FDA) has expanded the approval of Repatha ® ...

--Amgen today announced the presentation of 12 cardiovascular scientific research abstracts, including clinical trial and real-world evidence studies of Repatha ®, that add to the growing body of ...

A series of abstracts also made the case for serious gaps in GLP-1 treatment, which Amgen figures its investigational MariTide could fill. (Amgen, American Diabetes Association) As Amgen strives to ...

THOUSAND OAKS, Calif., Oct. 31, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new data from its cardiovascular portfolio, including late-breaking results from the Phase 3 VESALIUS-CV ...